Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG
Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the o...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Le, Quynh Thu [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
4 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole - 2012transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:71 ; year:2017 ; pages:180-183 ; extent:4 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.oraloncology.2017.05.022 |
|---|
| Katalog-ID: |
ELV035685387 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV035685387 | ||
| 003 | DE-627 | ||
| 005 | 20230625205217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2017.05.022 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017002000023.pica |
| 035 | |a (DE-627)ELV035685387 | ||
| 035 | |a (ELSEVIER)S1368-8375(17)30139-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 650 |q VZ |
| 084 | |a 85.03 |2 bkl | ||
| 084 | |a 31.80 |2 bkl | ||
| 084 | |a 54.80 |2 bkl | ||
| 084 | |a 50.03 |2 bkl | ||
| 100 | 1 | |a Le, Quynh Thu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. | ||
| 520 | |a Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. | ||
| 650 | 7 | |a Oropharyngeal neoplasms |2 Elsevier | |
| 650 | 7 | |a Therapies |2 Elsevier | |
| 650 | 7 | |a Meta-analysis as topic |2 Elsevier | |
| 650 | 7 | |a Head and neck neoplasms |2 Elsevier | |
| 650 | 7 | |a Organizations |2 Elsevier | |
| 650 | 7 | |a Clinical trials as topic |2 Elsevier | |
| 650 | 7 | |a Investigational |2 Elsevier | |
| 650 | 7 | |a Consensus |2 Elsevier | |
| 700 | 1 | |a Welch, John J. |4 oth | |
| 700 | 1 | |a Vermorken, Jan B. |4 oth | |
| 700 | 1 | |a Rischin, Danny |4 oth | |
| 700 | 1 | |a Mehanna, Hisham |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |d 2012transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV011194073 |
| 773 | 1 | 8 | |g volume:71 |g year:2017 |g pages:180-183 |g extent:4 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.oraloncology.2017.05.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OPC-MAT | ||
| 936 | b | k | |a 85.03 |j Methoden und Techniken der Betriebswirtschaft |q VZ |
| 936 | b | k | |a 31.80 |j Angewandte Mathematik |q VZ |
| 936 | b | k | |a 54.80 |j Angewandte Informatik |q VZ |
| 936 | b | k | |a 50.03 |j Methoden und Techniken der Ingenieurwissenschaften |q VZ |
| 951 | |a AR | ||
| 952 | |d 71 |j 2017 |h 180-183 |g 4 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
q t l qt qtl |
|---|---|
| matchkey_str |
lequynhthuwelchjohnjvermorkenjanbrischin:2017----:omtooaitrainlnegopooriaelnclras |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
85.03 31.80 54.80 50.03 |
| publishDate |
2017 |
| allfields |
10.1016/j.oraloncology.2017.05.022 doi GBVA2017002000023.pica (DE-627)ELV035685387 (ELSEVIER)S1368-8375(17)30139-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Le, Quynh Thu verfasserin aut Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG 2017transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus Elsevier Welch, John J. oth Vermorken, Jan B. oth Rischin, Danny oth Mehanna, Hisham oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:71 year:2017 pages:180-183 extent:4 https://doi.org/10.1016/j.oraloncology.2017.05.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 71 2017 180-183 4 045F 610 |
| spelling |
10.1016/j.oraloncology.2017.05.022 doi GBVA2017002000023.pica (DE-627)ELV035685387 (ELSEVIER)S1368-8375(17)30139-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Le, Quynh Thu verfasserin aut Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG 2017transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus Elsevier Welch, John J. oth Vermorken, Jan B. oth Rischin, Danny oth Mehanna, Hisham oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:71 year:2017 pages:180-183 extent:4 https://doi.org/10.1016/j.oraloncology.2017.05.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 71 2017 180-183 4 045F 610 |
| allfields_unstemmed |
10.1016/j.oraloncology.2017.05.022 doi GBVA2017002000023.pica (DE-627)ELV035685387 (ELSEVIER)S1368-8375(17)30139-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Le, Quynh Thu verfasserin aut Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG 2017transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus Elsevier Welch, John J. oth Vermorken, Jan B. oth Rischin, Danny oth Mehanna, Hisham oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:71 year:2017 pages:180-183 extent:4 https://doi.org/10.1016/j.oraloncology.2017.05.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 71 2017 180-183 4 045F 610 |
| allfieldsGer |
10.1016/j.oraloncology.2017.05.022 doi GBVA2017002000023.pica (DE-627)ELV035685387 (ELSEVIER)S1368-8375(17)30139-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Le, Quynh Thu verfasserin aut Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG 2017transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus Elsevier Welch, John J. oth Vermorken, Jan B. oth Rischin, Danny oth Mehanna, Hisham oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:71 year:2017 pages:180-183 extent:4 https://doi.org/10.1016/j.oraloncology.2017.05.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 71 2017 180-183 4 045F 610 |
| allfieldsSound |
10.1016/j.oraloncology.2017.05.022 doi GBVA2017002000023.pica (DE-627)ELV035685387 (ELSEVIER)S1368-8375(17)30139-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Le, Quynh Thu verfasserin aut Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG 2017transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus Elsevier Welch, John J. oth Vermorken, Jan B. oth Rischin, Danny oth Mehanna, Hisham oth Enthalten in Elsevier Science Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole 2012transfer abstract Amsterdam [u.a.] (DE-627)ELV011194073 volume:71 year:2017 pages:180-183 extent:4 https://doi.org/10.1016/j.oraloncology.2017.05.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT 85.03 Methoden und Techniken der Betriebswirtschaft VZ 31.80 Angewandte Mathematik VZ 54.80 Angewandte Informatik VZ 50.03 Methoden und Techniken der Ingenieurwissenschaften VZ AR 71 2017 180-183 4 045F 610 |
| language |
English |
| source |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:71 year:2017 pages:180-183 extent:4 |
| sourceStr |
Enthalten in Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole Amsterdam [u.a.] volume:71 year:2017 pages:180-183 extent:4 |
| format_phy_str_mv |
Article |
| bklname |
Methoden und Techniken der Betriebswirtschaft Angewandte Mathematik Angewandte Informatik Methoden und Techniken der Ingenieurwissenschaften |
| institution |
findex.gbv.de |
| topic_facet |
Oropharyngeal neoplasms Therapies Meta-analysis as topic Head and neck neoplasms Organizations Clinical trials as topic Investigational Consensus |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| authorswithroles_txt_mv |
Le, Quynh Thu @@aut@@ Welch, John J. @@oth@@ Vermorken, Jan B. @@oth@@ Rischin, Danny @@oth@@ Mehanna, Hisham @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011194073 |
| dewey-sort |
3610 |
| id |
ELV035685387 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035685387</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625205217.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2017.05.022</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017002000023.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035685387</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(17)30139-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Le, Quynh Thu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oropharyngeal neoplasms</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapies</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Meta-analysis as topic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck neoplasms</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Organizations</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical trials as topic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Investigational</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Consensus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Welch, John J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vermorken, Jan B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rischin, Danny</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mehanna, Hisham</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:71</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:180-183</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2017.05.022</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">71</subfield><subfield code="j">2017</subfield><subfield code="h">180-183</subfield><subfield code="g">4</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Le, Quynh Thu |
| spellingShingle |
Le, Quynh Thu ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG |
| authorStr |
Le, Quynh Thu |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011194073 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 650 - Management & auxiliary services |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus Elsevier |
| topic |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus |
| topic_unstemmed |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus |
| topic_browse |
ddc 610 ddc 650 bkl 85.03 bkl 31.80 bkl 54.80 bkl 50.03 Elsevier Oropharyngeal neoplasms Elsevier Therapies Elsevier Meta-analysis as topic Elsevier Head and neck neoplasms Elsevier Organizations Elsevier Clinical trials as topic Elsevier Investigational Elsevier Consensus |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j j w jj jjw j b v jb jbv d r dr h m hm |
| hierarchy_parent_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| hierarchy_parent_id |
ELV011194073 |
| dewey-tens |
610 - Medicine & health 650 - Management & public relations |
| hierarchy_top_title |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011194073 |
| title |
Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG |
| ctrlnum |
(DE-627)ELV035685387 (ELSEVIER)S1368-8375(17)30139-2 |
| title_full |
Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG |
| author_sort |
Le, Quynh Thu |
| journal |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| journalStr |
Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
180 |
| author_browse |
Le, Quynh Thu |
| container_volume |
71 |
| physical |
4 |
| class |
610 610 DE-600 610 VZ 650 VZ 85.03 bkl 31.80 bkl 54.80 bkl 50.03 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Le, Quynh Thu |
| doi_str_mv |
10.1016/j.oraloncology.2017.05.022 |
| dewey-full |
610 650 |
| title_sort |
formation of an international intergroup to coordinate clinical trials in head and neck cancers: hncig |
| title_auth |
Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG |
| abstract |
Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. |
| abstractGer |
Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. |
| abstract_unstemmed |
Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OPC-MAT |
| title_short |
Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG |
| url |
https://doi.org/10.1016/j.oraloncology.2017.05.022 |
| remote_bool |
true |
| author2 |
Welch, John J. Vermorken, Jan B. Rischin, Danny Mehanna, Hisham |
| author2Str |
Welch, John J. Vermorken, Jan B. Rischin, Danny Mehanna, Hisham |
| ppnlink |
ELV011194073 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1016/j.oraloncology.2017.05.022 |
| up_date |
2024-07-06T18:12:35.381Z |
| _version_ |
1803854340824236032 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV035685387</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625205217.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.oraloncology.2017.05.022</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017002000023.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV035685387</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1368-8375(17)30139-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">650</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">85.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">31.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.80</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">50.03</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Le, Quynh Thu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Clinical trials in head and neck cancer (HNC) face multiple challenges including low global incidence, excessive patient comorbidity rate, high treatment-related toxicity and more recently a changing tumor biology landscape. As clinical trials evolve to address new knowledge about HNC biology, the overall pool of eligible patients for each trial becomes smaller, leading to more accrual challenges. These challenges have led to the formation of the Head and Neck Cancer Intergroup (HNCIG) comprised of large HNC international and national cooperative groups and sites with the goal of facilitating the conduct of high quality clinical trials in a timely manner to improve outcomes in HNC. This article describes the objectives, structure, and activities of the HNCIG.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oropharyngeal neoplasms</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Therapies</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Meta-analysis as topic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Head and neck neoplasms</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Organizations</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clinical trials as topic</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Investigational</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Consensus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Welch, John J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vermorken, Jan B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rischin, Danny</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mehanna, Hisham</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole</subfield><subfield code="d">2012transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011194073</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:71</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:180-183</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.oraloncology.2017.05.022</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-MAT</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">85.03</subfield><subfield code="j">Methoden und Techniken der Betriebswirtschaft</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">31.80</subfield><subfield code="j">Angewandte Mathematik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.80</subfield><subfield code="j">Angewandte Informatik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">50.03</subfield><subfield code="j">Methoden und Techniken der Ingenieurwissenschaften</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">71</subfield><subfield code="j">2017</subfield><subfield code="h">180-183</subfield><subfield code="g">4</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3990517 |